 | Joel R SaperMichigan Head Pain and Neurological Institute, Ann Arbor, MI, USA. | Michigan Headache & Neurological Institute, Ann Arbor, MI, USA | Michigan Headache and Neurological ... |
Is this your profile? Claim your profile Copy URL Embed Link to your profile |
Joel R Saper:Expert Impact
Concepts for whichJoel R Saperhas direct influence:Chronic migraine,Acute treatment,Naproxen sodium,Chronic daily headache,Acute migraine,Episodic migraine,Migraine headache,Oral solution.
Joel R Saper:KOL impact
Concepts related to the work of other authors for whichfor which Joel R Saper has influence:Chronic migraine,Cluster headache,Botulinum toxin,Acute treatment,Medication overuse.
KOL Resume for Joel R Saper
| Year | |
|---|---|
| 2022 | Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA. |
| 2020 | Michigan Headache & Neurological Institute, Ann Arbor, MI, USA |
| 2017 | Michigan Headache and Neurological Institute Ann Arbor MI |
| 2016 | Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA |
| 2015 | Founder & Director of MHNI, Clinical Professor of Neurology, Ann Arbor, Michigan, USA. Michigan Head Pain & Neurological Institute Ann Arbor MI USA |
| 2013 | Michigan Head‐Pain & Neurological Institute Ann Arbor MI USA |
| 2012 | From the Headache Research and Treatment Program (J.M.H., A.C.), Department of Neurology, University of California Los Angeles, Los Angeles; Departments of Neurology, Epidemiology, and Population Health, and the Montefiore Headache Center (R.B.L.), Albert Einstein College of Medicine, Bronx, NY; Department of Neurology (D.W.D.), Mayo Clinic Arizona, Phoenix; Department of Neurology and the Jefferson Headache Center (S.D.S.), Thomas Jefferson University Hospital, Philadelphia, PA; Michigan Head Pain and Neurological Institute (J.R.S.), Ann Arbor; Swedish Pain Center (S.K.A.), Seattle, WA; Headache Group (P.J.G.), Department of Neurology, University of California, San Francisco; and Danish Headache Center (J.M.H.), Department of Neurology, Glostrup Hospital, University of Copenhagen, Denmark. Michigan Head Pain & Neurological Institute, USA |
| 2010 | Michigan Head–Pain and Neurological Institute, USA. |
| 2009 | From the Michigan Head‐Pain and Neurological Institute, Ann Arbor, MI, USA Department of Neurology, Michigan Head Pain and Neurological Institute, Ann Arbor, Michigan |
| 2008 | From the Jefferson Headache Center (S.S.), Thomas Jefferson University, Philadelphia, PA; Michigan Head Pain and Neurological Institute (J.S.), Ann Arbor; Child Neurology Associates (F.B.), Atlanta, GA; and Novartis Pharmaceuticals (M.S., K.M., J.D.), East Hanover, NJ. Michigan State University, USA. |
| 2007 | From the Mayo Clinic College of Medicine, Department of Neurology, Scottsdale, AZ, USA (Dr. Dodick); Jefferson Headache Center, Philadelphia, PA, USA (Dr. Silberstein); Michigan Head Pain and Neurological Institute, Ann Arbor, MI, USA (Dr. Saper); Diamond Headache Clinic, Chicago, IL, USA (Dr. Freitag); Headache Care Center, Springfield, MO, USA (Dr. Cady); UCLA School of Medicine, Department of Neurology, Los Angeles, CA, USA (Dr. Rapoport); Houston Headache Clinic, Houston, TX, USA (Dr. Mathew); Ortho‐McNeil Janssen, Scientific Affairs, LLC, Titusville, NJ, USA (Drs. Hulihan, Crivera, Rupnow, Mao, Finlayson, and Greenberg) Michigan Head Pain & Neurological Institute, Ann Arbor, Michigan; |
| 2006 | Michigan Head Pain & Neurological Institute, Ann Arbor, USA. |
| 2005 | Address all correspondence to Dr. Joel R. Saper, Michigan Head Pain and Neurological Institute, 3120 Professional Drive, Ann Arbor, MI 48104 |
| 2004 | From the Michigan Head-Pain and Neurological Institute, Ann Arbor. |
| 2003 | 3120 Professional Drive From the Departments of Neurology (Drs. Lipton and Bigal) and Epidemiology and Social Medicine (Dr. Lipton), Albert Einstein College of Medicine, Bronx, NY; Department of Neurology (Dr. Silberstein), Thomas Jefferson University School of Medicine, Jefferson Headache Center, Thomas Jefferson University Hospital, Philadelphia, PA; Michigan Head Pain and Neurological Institute (Dr. Saper), Ann Arbor, MI; The New England Center for Headache (Dr. Bigal), Stamford, CT; and The National Hospital for Neurology and Neurosurgery (Dr. Goadsby), Queen Square, London, UK. Michigan Head‐Pain and Neurological Institute Ann Arbor, MI 48104 |
| 2002 | From Michigan Head‐Pain and Neurological Institute, Ann Arbor |
| 2001 | Michigan Head Pain and Neurological Institute, 3120 Professional Dr, Ann Arbor, MI 48104-5131, USA. |
| 2000 | Drs. Lake and Saper with the Michigan Head Pain and Neurological Institute, Ann Arbor From the Head Pain Treatment Unit at Chelsea Community Hospital Diamond Headache Clinic, Chicago, IL, USA. |
| 1999 | From the Michigan Head‐Pain and Neurological Institute, Ann Arbor. Michigan Head, Pain, and Neurological Institute, Ann Arbor, Michigan 48104, USA. |
| 1997 | From the Cleveland Clinic Foundation (Dr. Solomon), Cleveland, OH; the Headache Care Center (Dr. Cady), Springfield, MO; the colorado Neurology and Headache Center (Dr. Klapper), Denver, CO; the Duke University Medical Center, Durham, and Glaxo Wellcome Inc (Dr. Earl), Research Triangle Park, NC; the Michigan Head-Pain and Neurological Institute (Dr. Saper), Ann Arbor, MI; and the Headache Center (Dr. Ramadan), Henry Ford Hospital, Detroit, MI. Michigan Headache and Neurological Institute, Ann Arbor, MI, USA; |
| 1996 | Michigan Head Pain and Neurologic Institute, Ann Arbor; |
| 1995 | Michigan Head Pain & Neurological Institute |
| 1994 | Michigan Head‐Pain and Neurological Institute, Ann Arbor, Michigan |
| 1992 | Michigan Head-Pain and Neurological Institute, Michigan State University, Ann Arbor. |
| 1990 | Director, Michigan Head Pain and Neurological Institute, Ann Arbor; Clinical Professor of Medicine (Neurology), Michigan State University, East Lansing, Michigan; and President, American Association for the Study of Headache |
| 1989 | Director, Michigan Headache and Neurological Institute, Associate Clinical Professor of Medicine (Neurology), Michigan State University, Ann Arbor, Michigan |
| 1988 | Michigan Headache and Neurological Institute, 3120 Professional Drive, Ann Arbor, MI 48104 U.S.A. |
| 1987 | Director, Michigan Headache and Neurological Institute, and Associate Clinical Professor of Medicine (Neurology), Michigan State University, Ann Arbor, Michigan Ann Arbor, MI. |
| 1986 | Michigan Headache and Neurological Institute, P.C., Ann Arbor, Michigan, U.S.A. |
| 1983 | Director, Michigan Headache and Neurological Institute, Ann Arbor, Michigan |
| Concept | World rank |
|---|---|
| tizanidine headache | #1 |
| emergent injection | #1 |
| severe migraine headache | #1 |
| intractable cases consequence | #1 |
| open‐label dose‐titration | #1 |
| cot daily | #1 |
| opinions prophylaxis | #1 |
| efficacy isometheptene | #1 |
| 50 75 bms180048 | #1 |
| treatment approaches relief | #1 |
| moh outpatient setting | #1 |
| phrase troubling encounters | #1 |
| recognition treatment alternatives | #1 |
| article changing perspectives | #1 |
| headache average | #1 |
| opioid butalbital overuse | #1 |
| current central brain | #1 |
| propranolol 160 | #1 |
| saper | #1 |
| chronic migraine disorders | #1 |
| perspectives migraine | #1 |
| behavioral therapy therapists | #1 |
| migraine bms180048 | #1 |
| 78 sumatriptan | #1 |
| hyperalgesia narcotics pain | #1 |
| drug treatment headache | #1 |
| patients sumatriptan succinate | #1 |
| glabellar 9 | #1 |
| physician requirements cot | #1 |
| benefits dosages | #1 |
| isometheptene mucate | #1 |
| transformational migraine | #1 |
| troubling encounters | #1 |
| adjustable stimulation | #1 |
| 3 hours dihydroergotamine | #1 |
| transformation concept | #1 |
| bonta prevention | #1 |
| saper meter | #1 |
| tolerability tizanidine | #1 |
| historical prejudice patients | #1 |
| tizanidine effective prophylactic | #1 |
| migrainous tension | #1 |
| sympatholytic reaction rail | #1 |
| topiramate 50 day | #1 |
| treatment tizanidine | #1 |
| consequence dental pathology | #1 |
Prominent publications by Joel R Saper
OBJECTIVE: To assess the effectiveness of the nonprescription combination of acetaminophen, aspirin, and caffeine in alleviating migraine headache pain.
DESIGN: Three double-blind, randomized, parallel-group, single-dose, placebo-controlled studies.
SETTING: Private practice, referral centers, and general community.
PATIENTS: Migraineurs with moderate or severe headache pain who met International Headache Society diagnostic criteria for migraine with aura or without aura. The most ...
| Known for Migraine Headache | Aspirin Caffeine | Patients Pain | Nonprescription Combination | Nausea Photophobia |
Efficacy and Safety of Topiramate for the Treatment of Chronic Migraine: A Randomized, Double‐Blind, Placebo‐Controlled Trial
[ PUBLICATION ]
OBJECTIVE: To evaluate the efficacy and safety of topiramate (100 mg/day) compared with placebo for the treatment of chronic migraine.
METHODS: This was a randomized, placebo-controlled, parallel-group, multicenter study consisting of 16 weeks of double-blind treatment. Subjects aged 18 to 65 years with 15 or more headache days per month, at least half of which were migraine/migrainous headaches, were randomized 1:1 to either topiramate 100 mg/day or placebo. An initial dose of ...
| Known for Chronic Migraine | Placebo Treatment | Safety Topiramate | 100 Day | Baseline Monthly |
A Randomized, Double-Blind, Placebo-Controlled Study of Sumatriptan Nasal Spray in the Treatment of Acute Migraine in Adolescents
[ PUBLICATION ]
OBJECTIVE: To compare the efficacy and tolerability of sumatriptan nasal spray (NS; 5 mg, 10 mg, and 20 mg) with placebo for the treatment of acute migraine in adolescents.
METHODS: A randomized, double-blind, placebo-controlled, single-attack study was conducted in 653 US adolescents (12-17 years of age). Patients with at least a 6-month history of migraine, who met International Headache Society criteria for migraine (with or without aura) were eligible for participation. Headache ...
| Known for Acute Migraine | Headache Relief | 20 Placebo | 2 Hours | Sumatriptan Treatment |
Chronic Daily Headache Prophylaxis With Tizanidine: A Double‐Blind, Placebo‐Controlled, Multicenter Outcome Study
[ PUBLICATION ]
OBJECTIVE: To assess the efficacy of tizanidine hydrochloride versus placebo as adjunctive prophylactic therapy for chronic daily headache (chronic migraine, migrainous headache, or tension-type headache).
BACKGROUND: Tizanidine is an alpha2-adrenergic agonist that inhibits the release of norepinephrine at both the spinal cord and brain, with antinociceptive effects that are independent of the endogenous opioid system. Previous open-label studies have suggested the drug may be effective ...
| Known for Chronic Daily Headache | Tizanidine Placebo | 4 Weeks | Tension Type | Patients Completed |
CONTEXT: Small open-label and controlled trials suggest that the antiepileptic drug topiramate is effective for migraine prevention.
OBJECTIVE: To assess the efficacy and safety of topiramate for migraine prevention in a large controlled trial.
DESIGN, SETTING, AND PATIENTS: A 26-week, randomized, double-blind, placebo-controlled study was conducted during outpatient treatment at 52 North American clinical centers. Patients were aged 12 to 65 years and had a 6-month history of migraine ...
| Known for Migraine Prevention | Patients Topiramate | Randomized Controlled | 200 Placebo | Responder Rate |
Safety and efficacy of AMG 334 for prevention of episodic migraine: a randomised, double-blind, placebo-controlled, phase 2 trial
[ PUBLICATION ]
BACKGROUND: The calcitonin gene-related peptide (CGRP) pathway is a promising target for preventive therapies in patients with migraine. We assessed the safety and efficacy of AMG 334, a fully human monoclonal antibody against the CGRP receptor, for migraine prevention.
METHODS: In this multicentre, randomised, double-blind, placebo-controlled, phase 2 trial, patients aged 18-60 years with 4 to 14 migraine days per month were enrolled at 59 headache and clinical research centres in North ...
| Known for Amg 334 | Episodic Migraine | 2 Trial | Monoclonal Antibodies | Primary Endpoint |
BACKGROUND: Preliminary work suggests that single-pulse transcranial magnetic stimulation (sTMS) could be effective as a treatment for migraine. We aimed to assess the efficacy and safety of a new portable sTMS device for acute treatment of migraine with aura.
METHODS: We undertook a randomised, double-blind, parallel-group, two-phase, sham-controlled study at 18 centres in the USA. 267 adults aged 18-68 years were enrolled into phase one. All individuals had to meet international ...
| Known for Acute Treatment | Migraine Aura | Sham Stimulation | Transcranial Magnetic | Nausea Photophobia |
OBJECTIVE: To compare gabapentin with placebo for use as a prophylactic agent in patients with migraine (with or without aura). STUDY DESIGN AND TREATMENT: After screening, a 4-week, single-blind, placebo baseline period was followed by a 12-week, double-blind, treatment period. The 12-week treatment period consisted of a 4-week titration phase and an 8-week stable-dosing phase. During the 4-week titration phase, patients were started on one 300-mg capsule of gabapentin or matching ...
| Known for Patients Migraine | Gabapentin Placebo | 4 Week | Study Medication | Treatment Period |
OBJECTIVE: Currently, no drugs are Food and Drug Administration-approved for migraine prophylaxis in pediatric patients. The objective of this study was to evaluate the efficacy and safety of topiramate for migraine prevention in adolescents.
METHODS: Adolescents (12-17 years of age) with a >/=6-month history of migraine were assigned randomly to receive 16 weeks of daily treatment with topiramate (50 or 100 mg/day) or placebo. The primary efficacy measure was the percent reduction in ...
| Known for Migraine Prevention | Efficacy Safety | 17 Years | 50 Day | 12 Weeks |
Eptinezumab in episodic migraine: A randomized, double-blind, placebo-controlled study (PROMISE-1)
[ PUBLICATION ]
OBJECTIVE: To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of episodic migraine.
METHODS: The PRevention Of Migraine via Intravenous ALD403 Safety and Efficacy-1 (PROMISE-1) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with episodic migraine were randomized to eptinezumab 30 mg, 100 mg, 300 mg, or placebo for up to four ...
| Known for Episodic Migraine | Eptinezumab 100 | Preventive Treatment | Mmds Weeks | 300 Placebo |
OBJECTIVE: To determine if repetitive sphenopalatine ganglion (SPG) blocks with 0.5% bupivacaine delivered through the Tx360(®) are superior in reducing pain associated with chronic migraine (CM) compared with saline.
BACKGROUND: The SPG is a small concentrated structure of neuronal tissue that resides within the pterygopalatine fossa (PPF) in close proximity to the sphenopalatine foramen and is innervated by the maxillary division of the trigeminal nerve. From an anatomical and ...
| Known for Acute Treatment | Sphenopalatine Ganglion | Bupivacaine Saline | Spg Blockade | Chronic Migraine |
OBJECTIVE: The primary objective of this study was to compare the efficacy and tolerability of topiramate and amitriptyline in the prophylaxis of episodic migraine headache.
METHODS: This was a 26-week, multicenter, randomized, double-blind, double-dummy, parallel-group noninferiority study. Adults with 3 to 12 migraines per month were randomized in a 1:1 ratio to receive an initial dose of 25 mg/d of either topiramate or amitriptyline, subsequently titrated to a maximum of 100 mg/d (or ...
| Known for Migraine Prevention | Topiramate Amitriptyline | Life Msq | Weight Loss | Secondary Outcome |
OBJECTIVE: This study assessed the efficacy of diclofenac potassium for oral solution, a novel water-soluble buffered powder formulation, versus placebo for the acute treatment of migraine. Diclofenac potassium for oral solution has a time to maximum plasma concentration (Tmax) of 15 minutes, suggesting the potential for a rapid onset of therapeutic effects.
METHODS: This was a randomized, double-blind, parallel-group, placebo-controlled study conducted in 23 US centers. Adult sufferers ...
| Known for Oral Solution | Acute Treatment | Diclofenac Potassium | 30 Minutes | Headache Pain Nausea |
OBJECTIVE: To evaluate non-invasive vagus nerve stimulation (nVNS) as an acute cluster headache (CH) treatment.
BACKGROUND: Many patients with CH experience excruciating attacks at a frequency that is not sufficiently addressed by current symptomatic treatments.
METHODS: One hundred fifty subjects were enrolled and randomized (1:1) to receive nVNS or sham treatment for ≤1 month during a double-blind phase; completers could enter a 3-month nVNS open-label phase. The primary end point was ...
| Known for Acute Treatment | Nvns Sham | Cluster Headache | Ech Cch | Nerve Stimulation |
A Double-blind Study of Subcutaneous Dihydroergotamine vs Subcutaneous Sumatriptan in the Treatment of Acute Migraine
[ PUBLICATION ]
OBJECTIVE: To assess the efficacy and tolerability of subcutaneous dihydroergotamine mesylate (DHE-45) vs subcutaneous sumatriptan succinate (Imitrex) for the treatment of acute migraine with or without aura.
DESIGN: Double-blind, randomized trial with parallel treatment arms.
SETTING: Clinics and private neurology practices.
SUBJECTS: Patients of either sex, with migraine with or without aura, between the ages of 18 and 65 years.
INTERVENTIONS: Patients with moderate or severe head pain ...
| Known for Subcutaneous Dihydroergotamine | Acute Migraine | 24 Hours | Headache Relief | Treated Sumatriptan |
